Amicus Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. Welcome to the Tuesday morning of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Amicus Therapeutics, and speaking on behalf of the company is CEO, John Crowley. John?
Great. Thank you, Anupam, and good morning, everybody. Thanks for being here. We'll be making forward-looking statements, so I'll reference you to Slide #2. We describe Amicus as a rare company. And this slide will give you an overview of some of the key pieces of the company that we've been building and where we are today and I think, in large measure, why we're so excited about 2020. So again, the cornerstone of our success with Galafold, our precision small medicine for Fabry disease; our world-class biologic now in a Phase III study fully enrolled for Pompe
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |